Heart : official journal of the British Cardiac Society
-
To develop an ECG-based tool for rapid risk assessment of a cardiac cause of syncope in patients ≥40 years. ⋯ In patients ≥40 years with a syncopal event, a combination of seven ECG criteria enabled rapid assessment of the likelihood that syncope was due to a cardiac cause.
-
Randomized Controlled Trial Multicenter Study
Limit of detection of troponin discharge strategy versus usual care: randomised controlled trial.
The clinical effectiveness of a 'rule-out' acute coronary syndrome (ACS) strategy for emergency department patients with chest pain, incorporating a single undetectable high-sensitivity cardiac troponin (hs-cTn) taken at presentation, together with a non-ischaemic ECG, remains unknown. ⋯ The LoDED strategy facilitates safe early discharge in >40% of patients with chest pain. Clinical effectiveness is variable when compared with existing rule-out strategies and influenced by wider system factors.
-
Multicenter Study Comparative Study
Monitoring indirect impact of COVID-19 pandemic on services for cardiovascular diseases in the UK.
To monitor hospital activity for presentation, diagnosis and treatment of cardiovascular diseases during the COVID-19) pandemic to inform on indirect effects. ⋯ Substantial reductions in total and cardiovascular activities are likely to contribute to a major burden of indirect effects of the pandemic, suggesting they should be monitored and mitigated urgently.
-
Multicenter Study Comparative Study
Mid-regional proatrial natriuretic peptide for predicting prognosis in hypertrophic cardiomyopathy.
N-terminal probrain natriuretic peptide (NT-proBNP) predicts mortality and the development of heart failure in hypertrophic cardiomyopathy (HCM). Mid-regional proatrial natriuretic peptide (MR-proANP) is a stable by-product of production of atrial natriuretic peptide. We sought to compare the prognostic value of MR-proANP and NT-proBNP in HCM. ⋯ MR-proANP emerges as a valuable biomarker for the prediction of death and heart failure related events in patients with HCM.
-
Three-dimensional printing (3DP) is a novel technology with applications in healthcare, particularly for congenital heart disease (CHD). We sought to explore the spectrum of use of 3D printed CHD models (3D-CM) and identify knowledge gaps within the published body of literature to guide future research. ⋯ 3DP for CHD is a new technology with an evolving literature base. Most of the published literature are experiential reports as opposed to manuscripts on scientifically robust studies. Our study has identified gaps in the literature and addressed priority areas for future research.